Am. J. Respir. Crit. Care Med., Volume 161, Number 4, April 2000, 1247-1251

Exhaled Ethane Is Elevated in Cystic Fibrosis and Correlates with Carbon Monoxide Levels and Airway Obstruction

PAOLO PAREDI, SERGEI A. KHARITONOV, DAVID LEAK, PALLAV L. SHAH, DEREK CRAMER, MARGARET E. HODSON, and PETER J. BARNES

Department of Thoracic Medicine, National Heart and Lung Institute; Department of Biochemistry, Imperial College of Science, Technology, and Medicine, London; and Lung Function Unit and Cystic Fibrosis Department, Royal Brompton Hospital, London, United Kingdom

Ethane is produced from lipid peroxidation and can be measured in the exhaled air. Cystic fibrosis (CF) is characterized by recurrent respiratory infections, release of reactive oxygen species by inflammatory cells, and increased oxidative stress. We measured exhaled ethane in 23 CF subjects (mean age ± SEM, 21 ± 4 yr; 10 male, FEV₁ 62 ± 4%) and compared it with two other noninvasive markers of oxidative stress and inflammation, carbon monoxide (CO) and nitric oxide (NO). Exhaled ethane was collected during a flow and pressure-controlled exhalation into a reservoir discarding dead space air contaminated with ambient air. A sample (2 ml) of the expired air was analyzed by chromatography. Ethane levels were elevated in patients not on steroids (n = 13, 1.99 ± 0.20 ppb) compared with steroid-treated patients (n = 10, 0.67 ± 0.09 ppb, p < 0.01) and with 14 nonsmoking control (8 men, age 33 ± 2.8 yr) subjects (0.82 ± 0.40 ppb, p < 0.05). In patients not on steroid treatment ethane was correlated to airway obstruction as assessed by the ratio of residual volume to total lung capacity (RV/ TLC) (r = 0.66, p < 0.05) and exhaled CO (r = 0.65, p < 0.05). CO concentrations were also higher in patients not on steroid treatment (3.4 ± 0.2 ppm) than in steroid-treated patients (2.6 ± 0.1 ppm, p < 0.05), whereas NO concentrations were not influenced by steroid treatment (3.0 ± 0.4 ppm and 2.9 ± 0.2 ppm, p > 0.05) and were lower than in a control group (7.0 ± 0.4 ppb, p < 0.05). Exhaled ethane is elevated in CF, reduced in steroid-treated patients and correlates with CO and RV/TLC; therefore, it may be a useful noninvasive marker of oxidative stress.

This article has been cited by other articles:

				M. Barker, M. Hengst, J. Schmid, H-J. Buers, B. Mittermaier, D. Klemp, and R. Koppmann Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis Eur. Respir. J., May 1, 2006; 27(5): 929 - 936. [Abstract] [Full Text] [PDF]

				E. Papageorgiou, K. Kostikas, T. Kiropoulos, E. Karetsi, G. Mpatavanis, and K. I. Gourgoulianis Increased Oxidative Stress in Exudative Pleural Effusions: A New Marker for the Differentiation Between Exudates and Transudates? Chest, November 1, 2005; 128(5): 3291 - 3297. [Abstract] [Full Text] [PDF]

				P. J. Barnes, I. M. Adcock, and K. Ito Histone acetylation and deacetylation: importance in inflammatory lung diseases Eur. Respir. J., March 1, 2005; 25(3): 552 - 563. [Abstract] [Full Text] [PDF]

				H. Zhou, F. Lu, C. Latham, D. S. Zander, and G. A. Visner Heme Oxygenase-1 Expression in Human Lungs with Cystic Fibrosis and Cytoprotective Effects against Pseudomonas Aeruginosa In Vitro Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 633 - 640. [Abstract] [Full Text] [PDF]

				G. von Basum, H. Dahnke, D. Halmer, P. Hering, and M. Murtz Online recording of ethane traces in human breath via infrared laser spectroscopy J Appl Physiol, December 1, 2003; 95(6): 2583 - 2590. [Abstract] [Full Text]

				S. W. Terheggen-Lagro, M. W. Bink, H. J. Vreman, and C. K. van der Ent End-Tidal Carbon Monoxide Corrected for Lung Volume Is Elevated in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1227 - 1231. [Abstract] [Full Text] [PDF]

				G. E. Carpagnano, P. J. Barnes, D. M. Geddes, M. E. Hodson, and S. A. Kharitonov Increased Leukotriene B4 and Interleukin-6 in Exhaled Breath Condensate in Cystic Fibrosis Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1109 - 1112. [Abstract] [Full Text] [PDF]

				P. Paredi, S. A. Kharitonov, and P. J. Barnes Analysis of Expired Air for Oxidation Products Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): S31 - 37. [Abstract] [Full Text] [PDF]

				R. P. Bowler and J. D. Crapo Oxidative Stress in Airways: Is There a Role for Extracellular Superoxide Dismutase? Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): S38 - 43. [Abstract] [Full Text] [PDF]

				J.O.N. Lundberg, J. Palm, and K. Alving Nitric oxide but not carbon monoxide is continuously released in the human nasal airways Eur. Respir. J., July 1, 2002; 20(1): 100 - 103. [Abstract] [Full Text] [PDF]

				D. Morse and A. M. K. Choi Heme Oxygenase-1 . The "Emerging Molecule" Has Arrived Am. J. Respir. Cell Mol. Biol., July 1, 2002; 27(1): 8 - 16. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594. [Full Text] [PDF]

				P. MAESTRELLI, A. H. EL MESSLEMANI, O. DE FINA, Y. NOWICKI, M. SAETTA, C. MAPP, and L. M. FABBRI Increased Expression of Heme Oxygenase (HO)-1 in Alveolar Spaces and HO-2 in Alveolar Walls of Smokers Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1508 - 1513. [Abstract] [Full Text] [PDF]

				S. A. KHARITONOV and P. J. BARNES Exhaled Markers of Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1693 - 1722. [Full Text] [PDF]